1005209-42-6 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 6-bromopyrazolo[1,5-a]pyrimidine-2-carboxylate is used as a key intermediate in the synthesis of pharmaceutical agents for its potential biological activity. The presence of the bromine atom allows for further functionalization and modification, facilitating the development of new drugs with improved therapeutic properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Methyl 6-bromopyrazolo[1,5-a]pyrimidine-2-carboxylate serves as a valuable building block for the creation of novel compounds. Its unique structure allows researchers to explore its potential in the design of new molecules with targeted biological activities, contributing to the advancement of drug discovery and development.
Used in Organic Synthesis:
Methyl 6-bromopyrazolo[1,5-a]pyrimidine-2-carboxylate is utilized as a synthetic precursor in organic synthesis. Its versatile structure enables the synthesis of a wide range of compounds, including those with potential applications in various industries such as pharmaceuticals, agrochemicals, and materials science.
Used in Chemical Modification:
The bromine atom in Methyl 6-bromopyrazolo[1,5-a]pyrimidine-2-carboxylate makes it a suitable candidate for chemical modification. This allows for the introduction of various functional groups, enhancing the compound's reactivity and enabling its use in a broader range of applications, including the development of new materials and the improvement of existing ones.
Check Digit Verification of cas no
The CAS Registry Mumber 1005209-42-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,5,2,0 and 9 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1005209-42:
(9*1)+(8*0)+(7*0)+(6*5)+(5*2)+(4*0)+(3*9)+(2*4)+(1*2)=86
86 % 10 = 6
So 1005209-42-6 is a valid CAS Registry Number.
1005209-42-6Relevant articles and documents
HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS
-
Paragraph 128, (2021/08/27)
Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.
PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE OF MEDICINE
-
Page/Page column 20-21, (2008/06/13)
Substituted pyrazolopyrimidine derivatives of formula (I) wherein R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 independently represent e.g. hydrogen or C1-6-alkyl; R8 represents a radical R9 or a radical R10, whereby one of the two radicals R8 represents R9 and the other radical R8 represents Ret; R9 represents e.g. a phenyl or thiophene group, and R10 represents e.g. hydrogen or methyl; are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
